HOME >> MEDICINE >> NEWS
VELCADE (Bortezomib) receives European marketing authorisation

ghted that marketing authorisation for VELCADE has been granted, as it is the first major advance for patients with multiple myeloma in more than a decade, and marks the company's commitment to Oncology." said Ken Watters, European Medical Director, Ortho Biotech.

"The approval of VELCADE today brings renewed hope to thousands of European multiple myeloma patients and their families" said Eric Low, Executive Director, International Myeloma Foundation (UK). "The multiple myeloma advocacy community has campaigned tirelessly over the years for cutting edge treatments such as VELCADE to be made available to patients, this is a very proud day", he continued.

The findings of a pre-specified interim analysis from an ongoing phase III trial which compared VELCADE to dexamethasone in refractory multiple myeloma patients found a statistically significant improvement in time to disease progression the primary endpoint of the trial in patients receiving VELCADE compared to patients receiving high-dose dexamethasone. Patients in the control arm of the trial were given the opportunity to switch to VELCADE as soon as possible based on an interim analysis that found a statistically significant improvement in TTP in patients receiving VELCADE compared to patients receiving dexamethasone.

VELCADE has a generally predictable, manageable safety profile (with appropriate monitoring and if necessary, dose modification). VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. There are approximately 50 ongoing clinical trials (in Europe and the US) investigating the potential of VELCADE in all stages of multiple myeloma and other cancers.

A single licence has been granted to market VELCADE in the 15 member states of the EU, plus Norway and Iceland. In addition it will be available in the 10 accession countries.

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Ph
'"/>

Contact: Eva Reynolds
eva_reynolds@uk.bm.com
44-20-7831-6262
Burson-Marsteller
28-Apr-2004


Page: 1 2 3

Related medicine news :

1. VELCADE(TM) data confirms long-term survival
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
(Date:2/28/2015)... For those people who are unable to ... Applied Research Foundation (Meso Foundation) will broadcast its ... at 9:30 AM. , The live broadcast is free ... be accessed through any browser on a computer or ... is a unique event that covers important treatment information ...
(Date:2/28/2015)... 28, 2015 Pioneer Millworks reclaimed USA ... Architecture & Construction Materials Show, an annual, premier sustainable ... 1,000 suppliers and top manufacturers of the latest building ... products sourced and manufactured by Pioneer Millworks from ... in Japan at restaurants, hotels, retailers, and corporate offices. ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Dr. ... Central Coast area residents, recently announced a special offer ... It’s a treatment option for new and established patients ... 2015 with a bright, white smile, Dr. Patel and ... of $299, marked down from the regular price of ...
(Date:2/28/2015)... NY (PRWEB) February 28, 2015 A ... federal testosterone lawsuits that have been filed by law ... the second week in March, the Firm notes. ... website, parties involved in the federal litigation will meet ... matters related to prescription therapy treatments designed to raise ...
(Date:2/28/2015)... 2015 How would you describe ... There are all kinds of different leaders, each ... of the advantages and applications of different leadership ... a new product this spring called The Leadership ... connection between personality type, leadership, and success. The ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3
(Date:2/27/2015)... , February 27, 2015 ... new study showing you trends, R&D progress, and predicted ... heading? What are the commercial prospects for this ... you potential revenues and other trends to 2025, discussing ... report lets you assess regenerative medicine : cell-based ...
(Date:2/27/2015)... 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") ... financial results for its first quarter ended December 31, ... December 31, 2014, revenue was $1,336,685. Operating expenses were ... $0.02 per share.  Covalon,s President and ... pleased with the significant progress we have made over ...
(Date:2/27/2015)... , February 27, 2015 ... sein bahnbrechendes Überwachungssystem für kongestive Herzinsuffizienz (CHF) ... -     ... die ein neuartiges Herzüberwachungssystem für Patienten mit ... bekannt, dass sie ein Finanzierungsvorhaben über 5 ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2
Cached News: